-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3653 Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Program: Oral and Poster Abstracts
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Michael Slade, MD, MS1, Ravi Vij, MD, MBA1, Keith Stockerl-Goldstein, MD2, Mark A. Schroeder, MD2, Angela Vickroy, ANP2*, Margaret Kavanaugh, ANP-BC1*, Carmen Wilson, PA-C1* and Mark Fiala, PhD1*

1Division of Oncology, Washington University School of Medicine, Saint Louis, MO
2Division of Oncology, Washington University School of Medicine, St. Louis, MO

Receipt of subspecialty care at an NCI-designated cancer center (NCI-CC) is associated with improved
patient outcomes (Wolfson et al, Cancers 2016). However, only 45% of patients live within 1 hour of an
NCI-CC. One solution to improve access is to open satellite locations in underserved areas, with the
assumption that newly diagnosed patients will prefer care close to home. However, no data is available
on the impact of this approach on previously diagnosed patients within an NCI-CC-associated health
system. While some patients may prefer the convenience of a local clinic, other patients may be reluctant
to switch providers. Our institution recently opened a new clinic focused on plasma cell dyscrasias in an
underserved area. We performed a structured intervention to identify patients living in this community
and traveling to other locations for care, with the goal of offering them the opportunity to transition to
the newly opened clinic.


Patients were considered eligible for transfer if 1) they were receiving care for a plasma cell dyscrasia from
a specialist at our facility, 2) they lived within the satellite clinic catchment area and 3) treating team
determined the patient was appropriate for transition of care. In borderline cases, door-to-door time was
determined using Google Maps and patients were included if the time to the satellite clinic was less than
or equal to their current location. Clinic lists were screened weekly from August to December 2024 via
the electronic medical record. Lists of eligible patients were sent to the treating physician, who
determined if patient was appropriate to approach for transfer. The current clinical team offered
appropriate patients transition of care at a regularly scheduled visit. Patient transfers were tracked and
qualitative reasons for decision regarding transfer were determined via discussion with the treating team.
We identified 62 eligible patients among 3 providers for potential transfer. After screening, 28 patients
(45%) were excluded from potential transfer. Cited reasons to exclude patients by the treating team
included study participation (n = 6), planned return to referring physician (5), medical instability (2) and
current therapy not available at satellite clinic (2). 13 patients (21%) were excluded due to existing
relationships with treating team and were marked as “provider discretion.” Of the remaining 34 patients,
10 patients (29%) decided to transfer their care to the satellite clinic and are currently still receiving their
care at that location. 24 patients (71%) were approached and declined to transfer their care. Reasons for
declining transfer included comfort with current team (n= 10), superior convenience at current location
due to work or family responsibilities (7) and concern regarding quality of care at the new facility (2). Five
patients did not identify a specific reason for declining transfer.


Our report provides pilot data that a structured intervention to approach previously diagnosed patients
within a cancer center network and offer them transfer to a newly formed subspecialty clinic closer to
home is acceptable to both patients and providers. Approximately half of identified patients were
classified as acceptable for transfer by their current clinical teams, with 46% of ineligible patients being
excluded due to provider preference. Further, while most patients elected not to transfer, 29% of
approached patients found the convenience of a clinic within their community valuable enough to switch
clinical care teams. The most commonly cited reason for declining transfer was connection with current
team (53%), emphasizing importance of directing newly referred patients to satellite locations if
appropriate.

Disclosures: Slade: Natera: Research Funding; Pfizer: Research Funding. Vij: Sanofi, BMS, Takeda: Other, Patents & Royalties; Janssen, Pfizer, GSK, Regeneron, Karyopharm: Other, Patents & Royalties. Schroeder: Advarra: Honoraria; Incyte: Honoraria; Kura Oncology: Honoraria.

*signifies non-member of ASH